Treatments for pulmonary arterial hypertension

Respiratory Medicine

Volumn 100, Issue 5, 2006, Pages 765-774

  Liu, Chao ^a   Liu, Kunshen ^a   Ji, Zhenguo ^a   Liu, Gang ^a  

^a HEBEI MEDICAL UNIVERSITY   (China)

Author keywords

Endothelin receptor antagonists; Prostacyclin; Pulmonary arterial hypertension; Sildenafil

Indexed keywords

BERAPROST; BOSENTAN; CALCIUM CHANNEL BLOCKING AGENT; DIGOXIN; DIURETIC AGENT; ENDOTHELIN RECEPTOR ANTAGONIST; ILOPROST; OXYGEN; PHOSPHODIESTERASE V INHIBITOR; PLACEBO; PROSTACYCLIN; PROSTACYCLIN DERIVATIVE; SILDENAFIL; SITAXSENTAN; UNIPROST;

ANTICOAGULATION; CLINICAL TRIAL; COCHRANE LIBRARY; DEATH; DIARRHEA; DISEASE SEVERITY; DRUG ABSORPTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG ERUPTION; DRUG HALF LIFE; DRUG MECHANISM; DRUG MEGADOSE; FLUSHING; HEADACHE; HEART FAILURE; HUMAN; INJECTION PAIN; JAW DISEASE; LEG PAIN; LIVER TOXICITY; LOW DRUG DOSE; NAUSEA; NONHUMAN; PAIN; PATHOGENESIS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PULMONARY HYPERTENSION; QUALITY OF LIFE; RANDOMIZATION; REVIEW; SIDE EFFECT; SURVIVAL;

ANTIHYPERTENSIVE AGENTS; CALCIUM CHANNEL BLOCKERS; EPOPROSTENOL; HUMANS; HYPERTENSION, PULMONARY; PIPERAZINES; PLATELET AGGREGATION INHIBITORS; PURINES; RANDOMIZED CONTROLLED TRIALS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECEPTORS, ENDOTHELIN; SULFONES; VASODILATOR AGENTS;

EID: 33645847524     PISSN: 09546111     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.rmed.2006.01.021     Document Type: Review

References (44)

1. Runo J.R., and Loyd J.E. Primary pulmonary hypertension. Lancet 361 (2003) 1533-1544
2. Simonneau G., Galie N., Rubin L.J., et al. Clinical classification of pulmonary hypertension. J Am Coll Cardiol 43 (2004) 5S-12S
3. Voelkel N.F., Tuder R.M., and Weir E.K. In: Rubin L., and Rich S. (Eds). Primary pulmonary hypertension. Pathophysiology of primary pulmonary hypertension (1997), Marcel Dekker, New York 83-129
4. Giaid A., Yanagisawa M., Langleben D., et al. Expression of endothelin-1 in the lungs of patients with pulmonary hypertension. N Engl J Med 328 (1993) 1732-1739
5. Giaid A., and Saleh D. Reduced expression of endothelial nitric oxide synthase in the lungs of patients with pulmonary hypertension. N Engl J Med 333 (1995) 214-221
6. Christman B.W., McPherson C.D., Newman J.H., et al. An imbalance between the excretion of thromboxane and prostacyclin metabolites in pulmonary hypertension. N Engl J Med 327 (1992) 70-75
7. Rich S., Dantzker D.R., Ayres S.M., et al. Primary pulmonary hypertension. A national prospective study. Ann Intern Med 107 (1987) 216-223
8. D'Alonzo G.E., Barst R.J., Ayres S.M., et al. Survival in patients with primary pulmonary hypertension. Results from a national prospective registry. Ann Intern Med 115 (1991) 343-349
9. Miyamoto S., Nagaya N., Satoh T., et al. Clinical correlates and prognostic significance of six-minute walk test in patients with primary pulmonary hypertension. Comparison with cardiopulmonary exercise testing. Am J Respir Crit Care Med 161 (2000) 487-492
10. Sitbon O., Humbert M., Nunes H., et al. Long-term intravenous epoprostenol infusion in primary pulmonary hypertension: prognostic factors and survival. J Am Coll Cardiol 40 (2002) 780-788
11. Rich S., Seidlitz M., Dodin E., et al. The short-term effects of digoxin in patients with right ventricular dysfunction from pulmonary hypertension. Chest 114 (1998) 787-792
12. Sandoval J., Aguirre J.S., Pulido T., et al. Nocturnal oxygen therapy in patients with the Eisenmenger syndrome. Am J Respir Crit Care Med 164 (2001) 1682-1687
13. Fuster V., Steele P.M., Edwards W.D., Gersh B.J., McGoon M.D., and Frye R.L. Primary pulmonary hypertension: natural history and the importance of thrombosis. Circulation 70 (1984) 580-587
14. Rich S., Kaufmann E., and Levy P.S. The effect of high doses of calcium-channel blockers on survival in primary pulmonary hypertension. N Engl J Med 327 (1992) 76-81
15. Tuder R.M., Cool C.D., Geraci M.W., et al. Prostacyclin synthase expression is decreased in lungs from patients with severe pulmonary hypertension. Am J Respir Crit Care Med 159 (1999) 1925-1932
16. Paramothayan N.S., Lasserson T.J., Wells A.U., and Walters E.H. Prostacyclin for pulmonary hypertension in adults. In: Arnold E.M., Cates C.J., Lasserson T.J., Malouf R., and Stewart V. (Eds). The Cochrane Library (2005), Wiley, Chichester, UK [Issue 2]
17. Badesch D.B., Tapson V.F., McGoon M.D., et al. Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease. A randomized, controlled trial. Ann Intern Med 132 (2000) 425-434
18. Rubin L.J., Mendoza J., Hood M., et al. Treatment of primary pulmonary hypertension with continuous intravenous prostacyclin (epoprostenol). Results of a randomized trial. Ann Intern Med 112 (1990) 485-491
19. Barst R.J., Rubin L.J., Long W.A., et al. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. The Primary Pulmonary Hypertension Study Group. N Engl J Med 334 (1996) 296-302
20. Simonneau G., Barst R.J., Galie N., et al. Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: a double-blind, randomized, placebo-controlled trial. Am J Respir Crit Care Med 165 (2002) 800-804
21. McLaughlin V.V., Gaine S.P., Barst R.J., et al. Efficacy and safety of treprostinil: an epoprostenol analog for primary pulmonary hypertension. J Cardiovasc Pharmacol 41 (2003) 293-299
22. Laliberte K., Arneson C., Jeffs R., Hunt T., and Wade M. Pharmacokinetics and steady-state bioequivalence of treprostinil sodium (Remodulin) administered by the intravenous and subcutaneous route to normal volunteers. J Cardiovasc Pharmacol 44 (2004) 209-214
23. Olschewski H., Olschewski A., Rose F., et al. Physiologic basis for the treatment of pulmonary hypertension. J Lab Clin Med 138 (2001) 287-297
24. Higenbottam T., Butt A.Y., McMahon A., Westerbeck R., and Sharples L. Long-term intravenous prostaglandin (epoprostenol or iloprost) for treatment of severe pulmonary hypertension. Heart 80 (1998) 151-155
25. Olschewski H., Simonneau G., Galie N., et al. Inhaled iloprost for severe pulmonary hypertension. N Engl J Med 347 (2002) 322-329
26. Galie N., Manes A., and Branzi A. The new clinical trials on pharmacological treatment in pulmonary arterial hypertension. Eur Respir J 20 (2002) 1037-1049
27. Barst R.J., McGoon M., McLaughlin V., et al. Beraprost therapy for pulmonary arterial hypertension. J Am Coll Cardiol 41 (2003) 2119-2125
28. Galie N., Humbert M., Vachiery J.L., et al. Effects of beraprost sodium, an oral prostacyclin analogue, in patients with pulmonary arterial hypertension: a randomized, double-blind, placebo-controlled trial. J Am Coll Cardiol 39 (2002) 1496-1502
29. Liu C., and Chen J. Endothelin receptor antagonists for pulmonary arterial hypertension. In: Arnold E.M., Cates C.J., Lasserson T.J., Malouf R., and Stewart V. (Eds). The Cochrane Library (2005), Wiley, Chichester, UK [Issue 1]
30. Barst R.J., Langleben D., Frost A., et al. Sitaxsentan therapy for pulmonary arterial hypertension. Am J Respir Crit Care Med 169 (2004) 441-447
31. Rubin L.J., Badesch D.B., Barst R.J., et al. Bosentan therapy for pulmonary arterial hypertension. N Engl J Med 346 (2002) 896-903
32. Channick R.N., Simonneau G., Sitbon O., et al. Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo-controlled study. Lancet 358 (2001) 1119-1123
33. Weimann J., Ullrich R., Hromi J., et al. Sildenafil is a pulmonary vasodilator in awake lambs with acute pulmonary hypertension. Anesthesiology 92 (2000) 1702-1712
34. Kanthapillai P., Lasserson T., and Walters E. Sildenafil for pulmonary hypertension. In: Arnold E.M., Cates C.J., Lasserson T.J., Malouf R., and Stewart V. (Eds). The Cochrane Library (2004), Wiley, Chichester, UK [Issue 4]
35. Sastry B.K., Narasimhan C., Reddy N.K., and Raju B.S. Clinical efficacy of sildenafil in primary pulmonary hypertension: a randomized, placebo-controlled, double-blind, crossover study. J Am Coll Cardiol 43 (2004) 1149-1153
36. Bharani A., Mathew V., Sahu A., and Lunia B. The efficacy and tolerability of sildenafil in patients with moderate-to-severe pulmonary hypertension. Indian Heart J 55 (2003) 55-59
37. Ghofrani H.A., Wiedemann R., Rose F., et al. Combination therapy with oral sildenafil and inhaled iloprost for severe pulmonary hypertension. Ann Intern Med 136 (2002) 515-522
38. Ghofrani H.A., Wiedemann R., Rose F., et al. Sildenafil for treatment of lung fibrosis and pulmonary hypertension: a randomised controlled trial. Lancet 360 (2002) 895-900
39. Galie N., Ghofrani H.A., Torbicki A., et al. Sildenafil citrate therapy for pulmonary arterial hypertension. N Engl J Med 353 (2005) 2148-2157
40. Sitbon O., Humbert M., Jais X., et al. Long-term response to calcium channel blockers in idiopathic pulmonary arterial hypertension. Circulation 111 (2005) 3105-3111
41. Galie N., Torbicki A., Barst R., et al. Guidelines on diagnosis and treatment of pulmonary arterial hypertension. The task force on diagnosis and treatment of pulmonary arterial hypertension of the European Society of Cardiology. Eur Heart J 25 (2004) 2243-2278
42. Galie N., Seeger W., Naeije R., Simonneau G., and Rubin L.J. Comparative analysis of clinical trials and evidence-based treatment algorithm in pulmonary arterial hypertension. J Am Coll Cardiol 43 (2004) 81S-88S
43. Humbert M., Barst R.J., Robbins I.M., et al. Combination of bosentan with epoprostenol in pulmonary arterial hypertension: BREATHE-2. Eur Respir J 24 (2004) 353-359
44. Hoeper M.M., Markevych I., Spiekerkoetter E., Welte T., and Niedermeyer J. Goal-oriented treatment and combination therapy for pulmonary arterial hypertension. Eur Respir J 26 (2005) 858-863